Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer.
Rönnlund C, Sifakis EG, Schagerholm C, Yang Q, Karlsson E, Chen X, Foukakis T, Weidler J, Bates M, Fredriksson I, Robertson S, Hartman J.
Rönnlund C, et al. Among authors: karlsson e.
Breast Cancer Res. 2024 Feb 7;26(1):24. doi: 10.1186/s13058-024-01779-9.
Breast Cancer Res. 2024.
PMID: 38321542
Free PMC article.